
Ep. 314 Exploring PARP Inhibitor Combinations in Prostate Cancer with Dr. Rana McKay and Dr. Emmanuel Antonarakis
With multiple clinical trials evaluating PARP inhibitor combinations, how do clinicians determine the best approach for advanced prostate cancer? In this episode of BackTable Urology, Dr. Alan Tan is joined by Dr. Rana McKay and Dr. Emmanuel Antonarakis to discuss how evolving evidence, patient selection, timing, toxicity, and genetic testing are shaping the use of PARP inhibitor combinations in clinical practice. --- Get the BackTable app https://www.backtable.com/app --- This podcast is supported by an educational grant from Pfizer. --- Timestamps 00:00 - Introduction 02:51 - PARPi Basics 14:12 - Major Study Differences 19:00 - Timing and Selection of PARPi Combinations 26:39 - Case: Somatic BRCA2 loss and mHSPC 35:51 - Case Continued: BRCA2 Reversion 39:57 - BRCAAway Study 42:59 - Takeaways from the 2026 APCCC --- More about this episode The conversation reviews lessons learned from major clinical trials, including PROpel, MAGNITUDE, TALAPRO-2, and AMPLITUDE, and addresses how these studies inform real-world treatment choices. The doctors dig into case examples, such as BRCA2 loss and reversion, and highlight practical strategies for using germline and somatic testing to personalize care. Key insights from the 2026 Advanced Prostate Cancer Consensus Conference are also shared, emphasizing the importance of precision medicine in this rapidly evolving field.
Publisher
BackTable Urology
Published
July 7, 2026
Duration
52 min
Format
Podcast
Category
Lifestyle · Medicine
Source
RSS feed
Host
BackTable Inc.
BackTable Urology
@backtableurology
#exploringparpinhibitor #prostatecancer #emmanuelantonarakis #medicine
